EU Prescribing Information

Vyxeos® Liposomal 44mg/100mg powder for concentrate for solution for infusion (Daunorubicin and cytarabine)
Please refer to local Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Purple lyophilised cake of powder for concentrate for solution for infusion. Each vial contains 44 mg daunorubicin and 100 mg cytarabine. After reconstitution the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine encapsulated in liposomes in a fixed combination in a 1:5 molar ratio. **Indication**: For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). **Dosage and administration**: Treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents. Do not interchange Vyxeos liposomal with other daunorubicin and/or cytarabine containing products. For intravenous infusion use only. An in-line membrane filter may be used provided the minimum pore diameter is greater than or equal to 15 µm. Do not administer via an intramuscular, intrathecal, or subcutaneous route. *Refer to full SmPC for detailed information on preparation of solution for infusion. Recommended dosing schedule for induction of remission*: 44 mg/100 mg/m^2, administered intravenously over 90 minutes on days 1, 3, and 5 as the first course of induction therapy; then on days 1 and 3 as subsequent course of induction therapy, if needed. *Recommended dosing schedule for consolidation:* Administer first consolidation cycle 5 to 8 weeks after the start of the last induction. Recommended dosing schedule is 29 mg/65 mg/m^2, administered intravenously over 90 minutes on days 1 and 3 as subsequent courses of consolidation therapy, if needed. Dose adjustments during treatment may be required in hypersensitivity symptoms and cardiotoxicity. Assessment of cardiac function prior to start of treatment is recommended. Patients should be monitored for haematologic response and toxicities. *Renal impairment***:** No dose adjustment required in mild, moderate or severe renal impairment. There is no experience in end-stage renal disease managed with dialysis. *Hepatic impairment:* No dose adjustment required for bilirubin level less than or equal to 50 µmol/L. There is no experience in hepatic impairment resulting in a bilirubin level greater than 50 µmol/L. *Elderly population (≥65 years):* No dose adjustment required*.* **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Special warnings and precautions:** Do not substitute or interchange with other daunorubicin and/or cytarabine-containing products. Severe myelosuppression and serious or fatal haemorrhagic events have been reported. Time to recovery of ANC and platelets may be prolonged and require additional monitoring. Monitor blood counts regularly until recovery. Prophylactic anti-infectives may be administered during the period of profound neutropenia until ANC returns to 500/µL or greater. Cardiotoxicity is a known risk; prior therapy with anthracyclines, pre-existing cardiac disease, previous radiotherapy of the mediastinum, or concomitant use of cardiotoxic products may increase the risk. Hepatic impairment may increase the risk of toxicity. Evaluation of hepatic function is recommended prior to administration and periodically during treatment. Monitor blood uric acid levels and initiate appropriate therapy if hyperuricemia develops. Each vial of Vyxeos liposomal contains 100 mg of copper gluconate. Only use in patients with a history of Wilson's disease or other copper-related disorder if the benefits outweigh the risks. Serious hypersensitivity reactions including anaphylactic reactions have been reported with daunorubicin and cytarabine. Avoid administration of live or live-attenuated vaccines. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished. Gastrointestinal mucositis and/or diarrhoea frequently occur and may influence the absorption of oral accompanying medicinal products. **Interactions**: Do not administer in combination with cardiotoxic agents unless cardiac function is closely monitored. Monitor hepatic function more frequently if co-administered with hepatotoxic agents. **Pregnancy, lactation and fertility:** There are no data on use in pregnant women. Do not use during pregnancy unless the benefit of treatment outweighs the risk. It is not known if Vyxeos liposomal is excreted in human milk therefore advise mothers to discontinue breastfeeding during therapy. Advise patients to avoid becoming pregnant while receiving Vyxeos liposomal. Male patients and women of childbearing potential must use an effective method of contraception during treatment and for 6 months following the last dose. Male fertility may be compromised by treatment. **Undesirable effects**: ***Please refer to the full SmPC for the complete list.*** Hypersensitivity, febrile neutropenia, oedema, diarrhoea/colitis, mucositis, fatigue, musculoskeletal pain, abdominal pain, decreased appetite, cough, headache, chills, arrhythmia, pyrexia, sleep disorders, and hypotension are the most frequently occurring adverse reactions (ADRs). Infection, cardiotoxicity and haemorrhage are the most serious and frequently occurring ADRs. **Storage and Handling**: Store in a refrigerator (2°C - 8°C). Vyxeos liposomal is cytotoxic; unused product or waste material should be disposed of in accordance with local requirements for cytotoxic agents. **Legal category**: Prescription only medicine (POM). **Marketing authorisation number**: EU/1/18/1308/001 **Package quantity and Cost**: carton containing 1 × 50 mL vial. Refer to local prescribing information for price. **Further information** is available from **Marketing Authorisation Holder**: Jazz Pharmaceuticals Ireland Ltd., 5th Floor, Waterloo Exchange, Waterloo Road, Dublin D04 E5W7, Ireland. **Date of revision:** July 2022. INT-VYX-1900009

Vyxeos® is a registered trademark of Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals subsidiary)

For country specific information please refer to your local SmPC or Product Monograph

Adverse events should be reported. Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). Adverse events should also be reported to Jazz Pharmaceuticals by email to medinfo-int@jazzpharma.com or phone via +353 1 968 1631 (may include an international call charge).